

Not entered

10/518128
D38047855
JT12 Rec'd PCT/PTO 14 DEC 2004

Perkins
Coie

James J. Zhu
PHONE: 310.788.3219
FAX: 310.843.1245
EMAIL: JZhu@perkinscoie.com

1620 26th Street
Sixth Floor, South Tower
Santa Monica, CA 90404-4013
PHONE: 310.788.9900
FAX: 310.788.3399
www.perkinscoie.com

June 22, 2004

Via Facsimile/Confirmation Copy via Courier
Fax No. 41 22 740 1435

International Bureau of WIPO
34 chemin des Colombettes
1211 Geneva 20
Switzerland

Amendment under PCT Article 19

Re: **AMYLIN PHARMACEUTICALS, INC.**
PCT Application No.: PCT/US03/18657
Our Docket No.: 54061.8101.WO00

Dear Sir or Madam:

The Authority established the International Preliminary Search Report based on the main invention. The claims drawn to the main invention are 1-4 and 19-22. Accordingly, in response to the International Preliminary Search Report dated April 22, 2004, please enter the following amendment under PCT Article 19. Originally filed claims 1 and 2 have been amended. Originally filed claims 3 and 4 remain unchanged. Originally filed claims 19-22 have been cancelled. A substitute sheet is enclosed containing this amendment.

Respectfully,



James J. Zhu

JJZ:ri

Enclosure

CERTIFICATE OF MAILING
(37 C.F.R. §1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being transmitted via facsimile (41 22 740 1435) on the date shown below to the International Bureau of WIPO, 34 chemin des Colombettes, 1211 Geneva 20, Switzerland.

Rena Iov

Name

June 22, 2004


Signature

ANCHORAGE · BEIJING · BELLEVUE · BOISE · CHICAGO · DENVER · HONG KONG · LOS ANGELES
MENLO PARK · OLYMPIA · PORTLAND · SAN FRANCISCO · SEATTLE · SPOKANE · WASHINGTON, D.C.

Perkins Coie LLP (Perkins Coie LLC in Illinois)

CLAIMS:

1. A method of treating an intestinal damage comprising the step of administering a pharmaceutically active formulation of PYY or a PYY agonist to a patient in need thereof.
2. The method of claim 1 wherein the intestinal damage is selected from the group consisting of inflammatory bowel disease, bowel atrophy, loss of bowel mucosa, and loss of bowel mucosal function.
3. The method of claim 2 wherein the inflammatory bowel disease is ulcerative colitis.
4. A method of using PYY or an agonist of PYY comprising the steps of: administering PYY or an agonist of PYY to a subject suffering from an intestinal damage selected from the group consisting of inflammatory bowel disease, bowel atrophy, loss of bowel mucosa, and loss of bowel mucosal function.